Business Context and Reporting Period
This Form 8-K Current Report was filed by Bionano Genomics, Inc. on April 13, 2023. The filing details the entry into a material definitive agreement and the issuance of unregistered equity securities. The primary purpose of these actions is to modify the voting structure required to approve a potential reverse stock split.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial transaction disclosed is the sale of one share of newly designated Series A Preferred Stock to David Barker, the Chair of the Board, for a purchase price of $100.00.
Material Changes Versus Prior Period
- Capital Structure: The Company issued one share of Series A Preferred Stock, which carries 3,000,000,000 votes.
- Voting Rights: Approval of a Reverse Stock Split Proposal now requires affirmative approval from a majority of the voting power of Common Stock and the Series A Preferred Stock voting together as a single class.
- Quorum Requirement: The Board amended the Company's Bylaws to reduce the quorum requirement for stockholder meetings from a majority of outstanding stock to one-third of outstanding stock.
- Abstention Impact: The Series A Preferred Stock is designed to vote in the same proportion as Common Stock votes actually cast (excluding abstentions). Consequently, abstentions and non-votes will no longer effectively count as votes against a Reverse Stock Split Proposal.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on future operations. The primary contingency described is the potential approval of a Reverse Stock Split Proposal. The Series A Preferred Stock includes specific terms:
- Redemption: The share will be redeemed for $100.00 automatically upon stockholder approval of a Reverse Stock Split Proposal or at the Board's discretion.
- Liquidation Preference: In a liquidation event, the holder is entitled to receive $100.00 before any payment to Common Stockholders.
- Transfer Restrictions: The share cannot be transferred prior to the approval of a Reverse Stock Split Proposal without Board consent.
Important Facts for Investor Verification
- Verify the specific terms of the Reverse Stock Split Proposal, including the proposed ratio, which is not detailed in this filing.
- Confirm the date and details of the upcoming stockholder meeting where the Reverse Stock Split Proposal will be presented.
- Review the full text of the Purchase Agreement (Exhibit 10.1) and the Certificate of Designation (Exhibit 3.1) for complete legal terms.
- Note that the Series A Preferred Stock was issued to an accredited investor (the Board Chair) under an exemption from registration.